BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 210 filers reported holding BRIDGEBIO PHARMA INC in Q4 2021. The put-call ratio across all filers is 0.63 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $661 | +60.8% | 25,068 | +4.9% | 0.00% | +33.3% |
| Q2 2023 | $411 | +19.5% | 23,904 | +15.4% | 0.00% | +50.0% |
| Q1 2023 | $344 | +124.8% | 20,722 | +3.0% | 0.00% | +100.0% |
| Q4 2022 | $153 | -99.9% | 20,122 | -7.3% | 0.00% | -50.0% |
| Q3 2022 | $216,000 | +74.2% | 21,716 | +78.5% | 0.00% | +100.0% |
| Q1 2022 | $124,000 | -42.9% | 12,168 | -6.5% | 0.00% | 0.0% |
| Q4 2021 | $217,000 | -57.1% | 13,008 | +20.4% | 0.00% | -66.7% |
| Q3 2021 | $506,000 | -3.4% | 10,803 | +25.7% | 0.00% | 0.0% |
| Q2 2021 | $524,000 | +42.8% | 8,594 | +44.2% | 0.00% | +50.0% |
| Q1 2021 | $367,000 | – | 5,959 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $55,099,000 | 39.31% |
| M28 Capital Management LP | 466,200 | $4,233,000 | 4.74% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $282,034,000 | 3.75% |
| Octagon Capital Advisors LP | 933,743 | $8,478,000 | 2.26% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $241,719,000 | 1.11% |
| HHLR ADVISORS, LTD. | 5,362,014 | $48,687,000 | 1.04% |
| Cormorant Asset Management, LP | 1,469,179 | $13,340,000 | 1.01% |
| Knott David M Jr | 213,206 | $1,936,000 | 0.81% |
| Fernwood Investment Management, LLC | 183,900 | $1,670,000 | 0.72% |
| HighVista Strategies LLC | 105,942 | $962,000 | 0.58% |